Repligen (NASDAQ:RGEN) Cut to “Hold” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Repligen (NASDAQ:RGEN – Free Report) from a buy rating to a hold rating in a research report sent to investors on Sunday morning.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Royal Bank Of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. Barclays began coverage on shares of Repligen in a report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price objective on the stock. Finally, Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $172.83.

Get Our Latest Stock Analysis on RGEN

Repligen Price Performance

NASDAQ:RGEN opened at $126.44 on Friday. The stock has a market cap of $7.10 billion, a P/E ratio of -280.98, a PEG ratio of 3.56 and a beta of 1.11. Repligen has a one year low of $102.97 and a one year high of $182.52. The company has a fifty day moving average price of $127.70 and a 200 day moving average price of $140.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter in the prior year, the company posted $0.28 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the 4th quarter worth approximately $29,000. Raiffeisen Bank International AG bought a new position in Repligen during the 4th quarter worth approximately $29,000. Twin Tree Management LP bought a new position in Repligen during the 1st quarter worth approximately $29,000. Finally, Itau Unibanco Holding S.A. bought a new position in Repligen during the 4th quarter worth approximately $40,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More